Trial of New Drug to Blocks Cell Changes Available at NIH Clinical Center

An oral drug that blocks activity of enzymes that change proteins in cells that leads to cancer is being tested at the National Institutes of Health. R935788 or Fostamatinib, a protein kinase inhibitor, is in a Phase II clinical trial for patients with several types of advanced cancer, including colorectal cancer.  Patients whose cancer has gotten…  Read More